Efficacy of interferon therapy on serum fibronectin levels in children with chronic hepatitis B infection

Helvacı, Mehmet Rami; Ozkaya, B; Ozbal, Ebru; Yaprak, Sema OzInel and Isin

doi:10.1046/j.1442-200x.1999.t01-1-01066.x

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few studies measured concentration of serum fibronectin in patients with chronic viral and alcoholic liver disease. [27,33,34] The level of serum fibronectin increased in our fibrotic patients with HCV infection agrees with Fortunato et al [27] Increased amounts of fibronectin are significant in the development of early liver fibrosis and fibronectin may act as a chemotactic factor for collagen producing cells and as a skeleton for the new collagen formation. [35] In the present study, the area under the ROC curve of fibronectin for discriminating patients with liver fibrosis from those with no fibrosis livers was 0.78.…”

Section: Discussionsupporting

confidence: 89%

Immunochemical Identification and Detection of Serum Fibronectin in Liver Fibrosis Patients with Chronic Hepatitis C

Attallah¹,

Zahran²,

Ismail³

et al. 2007

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

Serum tests measuring the dynamic processes of fibrogenesis and fibrolysis may reflect the severity of liver disease. Fibronectin plays a role in liver fibrosis. The aim of this study was to assess the diagnostic value of fibronectin in chronic HCV infection among Egyptian patients. Fibronectin was identified using specific monoclonal antibody and Western blot at 90-kDa in sera of HCV infected patients with liver fibrosis. The purified serum fibronectin showed one peak at 8 min when analyzed by capillary zone electrophoresis. Fibronectin was quantified in serum using ELISA. The mean (+SD) serum level of fibronectin (mg/L) in liver fibrosis patients were 450.9 (+170.3) and 230.5 (+90.3) in control individuals, respectively. There was a significant correlation between METAVIR score and serum fibronectin (r ¼ 0.401; P , 0.0001). The area under the receiver operating characteristic (ROC) curve of fibronectin for discriminating patients with liver fibrosis from those with no fibrosis livers and its p value were 0.78 and P , 0.0001. The efficiency of fibronectin for discriminating patients with liver fibrosis from those with non fibrosis livers was 75%. In conclusion, serum fibronectin can differentiate HCV infected patients with liver fibrosis from patients with non fibrosis.

show abstract

Section: Discussionsupporting

confidence: 89%

Immunochemical Identification and Detection of Serum Fibronectin in Liver Fibrosis Patients with Chronic Hepatitis C

Attallah¹,

Zahran²,

Ismail³

et al. 2007

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

show abstract

“…found a positive correlation between leptin levels and fibrosis stage. Although Helvaci et al 23 . reported that serum fibronectin level, a biomarker of fibrosis in liver, is a predictor of response to IFN treatment, serum fibronectin levels of non‐responders were not investigated in the mentioned study.…”

Section: Discussionmentioning

confidence: 94%

Is leptin a predictive factor in the end of therapy response in chronic hepatitis B?

Selimoğlu

Ertekin

2005

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…In a study of a patient with lupus, Ben Dayan et al 11 claimed that immunoglobulin G antibodies against platelets or megakaryocytes caused the decreased platelet aggregation and consequent bleeding. In pa- tients with hepatitis, Helvaci et al 12 hypothesized a mediatory effect of increased fibronectin levels. In the current study, we attempted to activate the aggregation process in vitro with six different agonists known to stimulate platelets via different receptors.…”

Section: Discussionmentioning

confidence: 99%

Impaired platelet aggregation in melanoma patients treated with interferon‐α‐2b adjuvant therapy

Gutman

Schachter

Stopel

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDHigh‐dose interferon (INF)‐ α‐2b is the only Food and Drug Administration‐approved adjuvant treatment for patients with melanoma who are at high risk of recurrence. Although circumstantial evidence points to a potentially harmful effect of INF‐α‐2b on platelet function, to the authors' knowledge this has never been studied in humans.METHODSThe study group was comprised of patients who had undergone surgery for melanoma and were free of disease but at a high risk of recurrence. All patients were candidates for adjuvant INF treatment (high‐dose) and were undergoing routine evaluation to which platelet aggregation was added. Aggregation was triggered in standard fashion with adenosine diphosphate, epinephrine, collagen, thrombin, arachidonic acid, and ristocetin. Blood samples were drawn immediately before treatment, during the intravenous loading phase, during the subcutaneous maintenance phase, and 3–6 weeks after cessation of treatment. Patients receiving low‐dose, long‐standing INF‐α‐2b treatment also were tested. All results at each phase were compared with those of normal controls.RESULTSIn those patients receiving high‐dose INF‐α‐2b, ristocetin‐induced aggregation did not appear to be affected. However, the response to ≥ 1 of the other agonists was impaired in 5 of 6 samples during loading, 14 of 15 samples during the maintenance phase, and 8 of 13 samples after treatment, compared with only 1 of 8 samples before treatment (P = 0.025, P = 0.002, and P = 0.067, respectively). During treatment with low‐dose INF, platelet function was affected to a lesser extent.CONCLUSIONSINF treatment in melanoma patients appears to be associated with severe impairment of platelet aggregation, which appears to be dose‐dependent and cumulative–dose‐dependent. This is not detectable by the standard coagulation profile. This effect has significant implications in the event of accidental injury or elective surgery. The antiaggregation activity may be the mechanism by which INF delays, reduces, or prevents the formation of melanoma metastases. Cancer 2002;94:780–5. © 2002 American Cancer Society.DOI 10.1002/cncr.10261

show abstract

Efficacy of interferon therapy on serum fibronectin levels in children with chronic hepatitis B infection

Cited by 4 publications

References 8 publications

Immunochemical Identification and Detection of Serum Fibronectin in Liver Fibrosis Patients with Chronic Hepatitis C

Immunochemical Identification and Detection of Serum Fibronectin in Liver Fibrosis Patients with Chronic Hepatitis C

Is leptin a predictive factor in the end of therapy response in chronic hepatitis B?

Impaired platelet aggregation in melanoma patients treated with interferon‐α‐2b adjuvant therapy

Contact Info

Product

Resources

About